Niagen Bioscience (NAGE) Assets Average (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Assets Average of $110.4 million for Q1 2026, up 47.54% year-over-year from $74.8 million in Q1 2025, and up 7.92% quarter-over-quarter from $102.3 million in Q4 2025.
Niagen Bioscience (NAGE) Assets Average (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Assets Average for 14 consecutive years, with $110.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 47.54% year-over-year to $110.4 million; the TTM figure through Mar 2026 stood at $110.4 million (up 47.54% YoY), while the FY2025 annual figure was $87.3 million, up 41.74% from the prior year.
- Assets Average grew to $110.4 million in Q1 2026 per NAGE's latest filing, from $102.3 million in the prior quarter.
- Across five years, Assets Average topped out at $110.4 million in Q1 2026 and bottomed at $46.1 million in Q3 2022.
- Historically, Assets Average has averaged $65.4 million across 5 years, with a median of $54.5 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average slipped 26.93% — and 2025, when it surged 71.55%.
- Niagen Bioscience's Assets Average stood at $49.9 million in 2022, then climbed by 8.75% to $54.2 million in 2023, then advanced by 15.08% to $62.4 million in 2024, then jumped by 63.9% to $102.3 million in 2025, then grew by 7.92% to $110.4 million in 2026.
- Business Quant data shows NAGE's Assets Average at $110.4 million in Q1 2026, $102.3 million in Q4 2025, and $94.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 110.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.46 Mn |
| Mar 31, 2026 | 110.37 Mn |
| Dec 31, 2025 | 102.27 Mn |
| Sep 30, 2025 | 94.83 Mn |
| Jun 30, 2025 | 86.43 Mn |
| Mar 31, 2025 | 74.81 Mn |
| Dec 31, 2024 | 62.40 Mn |
| Sep 30, 2024 | 55.28 Mn |
| Jun 30, 2024 | 54.06 Mn |
| Mar 31, 2024 | 54.52 Mn |
| Dec 31, 2023 | 54.22 Mn |
| Sep 30, 2023 | 53.33 Mn |
| Jun 30, 2023 | 53.47 Mn |
| Mar 31, 2023 | 53.91 Mn |
| Dec 31, 2022 | 49.86 Mn |
| Sep 30, 2022 | 46.14 Mn |
| Jun 30, 2022 | 49.77 Mn |
| Mar 31, 2022 | 55.39 Mn |
| Dec 31, 2021 | 59.15 Mn |
| Sep 30, 2021 | 63.15 Mn |